Febrile Infection-Related Epilepsy Syndrome
Conditions
Interventions
Combined therapy Group:Tocilizumab + Anakinra
Sponsors
Beijing Childrens Hospital,Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age 29 days to 18 years; 2. Meets the diagnostic criteria for FIRES; 3. First onset and can be included in the study during the acute phase of FIRES; 4. The child's guardian fully understands the study content and signs a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Allergy to anakinra or tocilizumab injection components; 2. Accompanied by severe heart or kidney failure; 3. FIRES children whose guardians, for various reasons, do not agree to use biological agents or discontinue treatment midway.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glasgow Coma Scale score of children at discharge; | — |
Secondary
| Measure | Time frame |
|---|---|
| Seizure control status;PICU Length of Stay;Duration of mechanical ventilation;Total hospital stay;In-hospital mortality rate;28-day in-hospital mortality;Short-term and long-term (1 month and 6 months after discharge) neurological function (PCPC/POPC); | — |
Countries
China
Contacts
Public ContactQuan Wang
Beijing Childrens Hospital,Capital Medical University
Outcome results
None listed